These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 29753347)

  • 21. Piloting the development of a cost-effective evidence-informed clinical pathway: managing hypertension in Jordanian primary care.
    Chalkidou K; Lord J; Obeidat NA; Alabbadi IA; Stanley AG; Bader R; Momani A; O'Mahony RM; Qatami L; Cutler D
    Int J Technol Assess Health Care; 2011 Apr; 27(2):151-8. PubMed ID: 21473813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic considerations in the provision of treatments for rare diseases.
    McCabe C; Edlin R; Round J
    Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.
    Hinde S; Epstein D; Cook A; Embleton A; Perren T; Sculpher M
    Value Health; 2016 Jun; 19(4):431-9. PubMed ID: 27325335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of decision analytic modeling in the health economic assessment of spinal intervention.
    Edwards NC; Skelly AC; Ziewacz JE; Cahill K; McGirt MJ
    Spine (Phila Pa 1976); 2014 Oct; 39(22 Suppl 1):S16-42. PubMed ID: 25299257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost of depression in Europe.
    Sobocki P; Jönsson B; Angst J; Rehnberg C
    J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mental health care system optimization from a health-economics perspective: where to sow and where to reap?
    Lokkerbol J; Weehuizen R; Mavranezouli I; Mihalopoulos C; Smit F
    J Ment Health Policy Econ; 2014 Jun; 17(2):51-60. PubMed ID: 25153093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012).
    Wonder M; Chin G
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):843-50. PubMed ID: 25938794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.
    Blommestein HM; Armstrong N; Ryder S; Deshpande S; Worthy G; Noake C; Riemsma R; Kleijnen J; Severens JL; Al MJ
    Pharmacoeconomics; 2016 Jan; 34(1):23-31. PubMed ID: 26314282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cost effectiveness and budget impact of natalizumab for formulary inclusion.
    Bakhshai J; Bleu-Lainé R; Jung M; Lim J; Reyes C; Sun L; Rochester C; Shaya FT
    J Med Econ; 2010 Mar; 13(1):63-9. PubMed ID: 20028199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature.
    IJzerman MJ; Koffijberg H; Fenwick E; Krahn M
    Pharmacoeconomics; 2017 Jul; 35(7):727-740. PubMed ID: 28432642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early Health Economic Modelling - Optimizing Development for Medical Device Developers? Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling".
    Teljeur C; Ryan M
    Int J Health Policy Manag; 2020 Sep; 9(9):403-405. PubMed ID: 32610765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Towards the automated economic assessment of newborn screening for rare diseases.
    Prieto-González D; Castilla-Rodríguez I; González E; Couce ML
    J Biomed Inform; 2019 Jul; 95():103216. PubMed ID: 31128259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rare diseases under different levels of economic analysis: current activities, challenges and perspectives.
    Cannizzo S; Lorenzoni V; Palla I; Pirri S; Trieste L; Triulzi I; Turchetti G
    RMD Open; 2018; 4(Suppl 1):e000794. PubMed ID: 30488003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Automated generation of decision-tree models for the economic assessment of interventions for rare diseases using the RaDiOS ontology.
    Prieto-González D; Castilla-Rodríguez I; González E; Couce ML
    J Biomed Inform; 2020 Oct; 110():103563. PubMed ID: 32931923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The real-world impact of National Institute for Health and Care Excellence's real-world evidence framework.
    Duffield S; Jónsson P
    J Comp Eff Res; 2023 Nov; 12(11):e230135. PubMed ID: 37855246
    [No Abstract]   [Full Text] [Related]  

  • 37. Expected Value of Sample Information with Imperfect Implementation: Improving Practice and Reducing Uncertainty with Appropriate Counterfactual Consideration.
    Eckermann S; Willan AR
    Med Decis Making; 2016 Apr; 36(3):282-3. PubMed ID: 26929164
    [No Abstract]   [Full Text] [Related]  

  • 38. Challenges of economic evaluation in rare diseases.
    Duckett S
    J Med Ethics; 2022 Feb; 48(2):93-94. PubMed ID: 35064069
    [No Abstract]   [Full Text] [Related]  

  • 39. Benefits, Challenges and Potential Strategies of Open Source Health Economic Models.
    Dunlop WCN; Mason N; Kenworthy J; Akehurst RL
    Pharmacoeconomics; 2017 Jan; 35(1):125-128. PubMed ID: 27928759
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.